ABOUT THIS EPISODE
Why do breakthrough medical technologies still fail to get adopted?
In this episode of Med Tech Gurus, we sit down with David Neale, Co-Founder and CEO of Argá MedTech, to explore what it really takes to bring a differentiated cardiac technology from concept to clinical adoption.
Argá is advancing next-generation pulsed field ablation (PFA) for the treatment of atrial fibrillation, with early data showing 100% procedural success, strong safety, and high lesion durability. But as David explains, great clinical data alone isn't enough.
Drawing on decades of experience in cardiac rhythm management, David shares why so many promising technologies fail—not because of engineering, but because they ignore physician workflow, hospital operations, and real-world usability. From designing a single, multi-configurable catheter platform to simplifying complex EP lab environments, Argá's strategy is built around one principle: innovation must fit the workflow to win adoption.
We dive into lessons from first-in-human trials, the importance of disciplined execution, and why companies must design for three critical stakeholders: clinicians, operational teams, and administrators. David also shares practical insights on site selection, physician alignment, and how to move from strong data to real-world adoption.
If you're interested in cardiac electrophysiology, pulsed field ablation, MedTech commercialization, clinical trials, or healthcare innovation, this episode delivers a powerful playbook for turning technology into adoption.
